Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Reaches New 1-Year High - What's Next?

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report)'s share price hit a new 52-week high during trading on Friday . The company traded as high as $105.30 and last traded at $104.96, with a volume of 1569702 shares. The stock had previously closed at $104.78.

Analyst Ratings Changes

Several research analysts have weighed in on VRNA shares. Wells Fargo & Company lowered Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating and reduced their target price for the stock from $138.00 to $107.00 in a report on Thursday, July 10th. Cantor Fitzgerald lifted their target price on Verona Pharma PLC American Depositary Share from $90.00 to $100.00 and gave the stock an "overweight" rating in a report on Wednesday, June 11th. Wolfe Research lowered Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 10th. Piper Sandler lowered Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 10th. Finally, HC Wainwright restated a "neutral" rating and issued a $107.00 price target (up from $90.00) on shares of Verona Pharma PLC American Depositary Share in a report on Monday, July 14th. Eleven research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, Verona Pharma PLC American Depositary Share currently has an average rating of "Hold" and a consensus target price of $109.00.

Verona Pharma PLC American Depositary Share Trading Up 0.1%

The company has a debt-to-equity ratio of 1.07, a current ratio of 8.86 and a quick ratio of 8.73. The business has a 50-day moving average of $87.55 and a 200-day moving average of $70.00. The firm has a market cap of $8.94 billion, a price-to-earnings ratio of -52.50 and a beta of 0.24.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $0.27 earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.49. The business had revenue of $98.65 million for the quarter, compared to analyst estimates of $41.47 million. Research analysts anticipate that Verona Pharma PLC American Depositary Share will post -1.95 EPS for the current year.

Insider Transactions at Verona Pharma PLC American Depositary Share

In related news, CFO Mark W. Hahn sold 400,000 shares of the business's stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $11.40, for a total value of $4,560,000.00. Following the completion of the sale, the chief financial officer directly owned 12,278,992 shares in the company, valued at approximately $139,980,508.80. The trade was a 3.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Kathleen A. Rickard sold 114,984 shares of the business's stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $8.82, for a total value of $1,014,158.88. Following the completion of the sale, the insider owned 2,546,472 shares of the company's stock, valued at approximately $22,459,883.04. This trade represents a 4.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,965,800 shares of company stock worth $20,056,881 over the last three months. Company insiders own 4.80% of the company's stock.

Institutional Investors Weigh In On Verona Pharma PLC American Depositary Share

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its stake in shares of Verona Pharma PLC American Depositary Share by 5.6% in the 2nd quarter. GAMMA Investing LLC now owns 1,940 shares of the company's stock valued at $183,000 after acquiring an additional 103 shares during the last quarter. Geneos Wealth Management Inc. lifted its stake in shares of Verona Pharma PLC American Depositary Share by 44.2% in the 1st quarter. Geneos Wealth Management Inc. now owns 630 shares of the company's stock valued at $40,000 after acquiring an additional 193 shares during the last quarter. Townsquare Capital LLC lifted its stake in shares of Verona Pharma PLC American Depositary Share by 1.9% in the 4th quarter. Townsquare Capital LLC now owns 17,958 shares of the company's stock valued at $834,000 after acquiring an additional 332 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Verona Pharma PLC American Depositary Share by 3.4% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,880 shares of the company's stock valued at $1,124,000 after acquiring an additional 394 shares during the last quarter. Finally, NBC Securities Inc. bought a new position in shares of Verona Pharma PLC American Depositary Share in the 1st quarter valued at $34,000. 85.88% of the stock is currently owned by institutional investors.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.